gave it a crack and in doing so inspired others
Richard Scolyer, one of the world's foremost cancer researchers, died in early June at fifty-nine from the very disease he had devoted his life to understanding. Diagnosed with an inoperable brain tumour in 2023 and given months to live, he turned his own illness into an act of public witness — continuing his research, sharing his journey with unflinching honesty, and demonstrating that the pursuit of meaning need not pause for mortality. His death closes a life that bridged the laboratory and the human heart, leaving behind both a body of science and a model of how to face the unknown.
- A terminal diagnosis in May 2023 gave one of Australia's most celebrated cancer specialists six to eight months to live — yet Scolyer kept working, kept cycling, and kept posting updates to 150,000 followers who watched alongside him.
- The experimental immunotherapy treatments he helped pioneer initially slowed his own tumour's growth, turning him into a living case study and offering a rare, intimate window into the frontier of cancer medicine.
- In March, two months before his death, he announced the cancer had progressed again — and responded not with despair but with characteristic resolve, describing it as 'a bit disappointing' while insisting there was still more to do.
- His public transparency reshaped how Australians understood both cancer and courage, prompting a state funeral announcement from the Prime Minister and an outpouring of grief from patients, colleagues, and strangers alike.
- The legacy he leaves — nine Premier's Awards for cancer research, a 2024 Australian of the Year honour shared with colleague Georgina Long, and a documented journey through terminal illness — will likely shape immunotherapy research and patient communication for years to come.
Richard Scolyer died on a Monday in early June, fifty-nine years old, from a cancer he had spent his career learning to fight. Diagnosed with grade-four glioblastoma in May 2023 and given six to eight months to live, he refused to disappear quietly. Instead, he became his own case study — undergoing experimental immunotherapy treatments he and his colleagues had pioneered, treatments that for a time slowed the tumour's growth. He kept working. He kept sharing updates with 150,000 followers, a running commentary on what it felt like to be a cancer specialist confronting his own mortality.
In March, two months before his death, he announced the cancer had progressed again. "Not the best day ever," he wrote — then noted he still had more to do, and was planning to cycle a four-day leg of the Tour de Cure charity event in Tasmania, the state where he had grown up. This was the texture of his final years: unflinching documentation of decline, paired with a stubborn refusal to stop living.
Before he died, Scolyer wrote a statement thanking Australians for letting him share his journey "warts and all." He hoped to be remembered as an ordinary Australian who "gave it a crack" — generous words, entirely in character, focused not on himself but on what might inspire others. Prime Minister Anthony Albanese confirmed a state funeral, describing how Scolyer had taken the nation into his confidence and shown what it meant to hope and to stand firm against fear.
His achievements were substantial: nine New South Wales Premier's Awards for cancer research, appointment as an Officer of the Order of Australia, and the 2024 Australian of the Year honour shared with colleague Georgina Long — recognition that arrived while he was already fighting his own tumour. A colleague remembered him as a "cheery, down-to-earth lad from Launceston" whose work had benefited cancer patients worldwide. He leaves behind a body of research that will outlast him, and a record of how one person chose to face the thing he had spent his life studying.
Richard Scolyer died on a Monday in early June, fifty-nine years old, from a cancer he had spent his career learning to fight. The world-renowned pathologist and melanoma specialist had been diagnosed with grade-four glioblastoma—an aggressive, inoperable brain tumor—in May 2023, given six to eight months to live, and then simply refused to disappear quietly.
Instead, he became his own case study. Scolyer underwent a series of experimental immunotherapy treatments that he and his colleagues had pioneered, the kind of cutting-edge work that had made him one of the most respected cancer researchers on the planet. For a time, the treatments worked. The tumor's growth slowed. He kept working. He kept posting updates to his 150,000 followers on Facebook, a running commentary on what it felt like to be a cancer specialist confronting his own mortality. In March, two months before his death, he announced the cancer had progressed again. "Not the best day ever," he wrote. "There seems to be further progression of my brain tumour … Whilst it is a bit disappointing, in the big picture it's not the end of the road and I've got more to do!"
He had meant it. A week before that scan, he had told his followers he was anxious about the results—but he was still planning to cycle in a four-day leg of the Tour de Cure charity event in Tasmania, the state where he had grown up. This was the texture of Scolyer's final years: the unflinching documentation of decline, paired with an almost stubborn refusal to stop living.
Before his death, Scolyer wrote a statement for Australians. He thanked them for their support, for allowing him to share his journey "warts and all." He said he hoped his legacy would be remembered as that of an ordinary Australian who "gave it a crack" and in doing so inspired others to pursue their dreams with humility, love, and compassion. It was the kind of thing people say when they know the end is near, and it was entirely in character: generous, unsentimental, focused on what came next for everyone else.
Prime Minister Anthony Albanese confirmed that Scolyer would receive a state funeral. "The world has lost one of our brightest lights and one of our biggest hearts," Albanese said. He described how Scolyer had taken the nation into his confidence as he battled his illness, how he had shown Australians what it meant to hope, to search for solutions, to stand firm against fear. The cancer specialist had become the subject of his own research, and in doing so had taught a country something about courage.
Scolyer's achievements in medicine were substantial. He had won the New South Wales Premier's Award for Outstanding Cancer Research nine times. In 2021, he was appointed an officer of the Order of Australia. But his most visible achievement came in 2024, when he and his co-medical director at Melanoma Institute Australia, Georgina Long, were jointly named Australian of the Year for their work on immunotherapy as a treatment for advanced melanoma. That recognition came while he was already sick, already fighting his own tumor, already documenting the fight for anyone who wanted to watch.
John Thompson, a colleague at Sydney University, remembered Scolyer as a "cheery, down-to-earth lad from Launceston" whose stellar career had produced benefits for countless cancer patients worldwide. The phrase "lad from Launceston" captures something of how Scolyer had positioned himself throughout his illness: not as a distant expert, but as someone from somewhere, someone who had given it a crack and wanted others to do the same. His death leaves behind a body of research that will outlast him, and a record of how one person chose to face the thing he had spent his life studying.
Citas Notables
Not the best day ever. There seems to be further progression of my brain tumour … Whilst it is a bit disappointing, in the big picture it's not the end of the road and I've got more to do!— Richard Scolyer, March 2026, announcing cancer progression on Facebook
The world has lost one of our brightest lights and one of our biggest hearts. Every day, this remarkable man took us into his confidence and he lifted us all in the process.— Prime Minister Anthony Albanese
La Conversación del Hearth Otra perspectiva de la historia
What made Scolyer's approach to his own illness so different from how most people in his position might have handled it?
He didn't hide. Most people, especially someone with his stature, might have retreated into privacy. Instead he posted updates to 150,000 people. He was transparent about the fear, the setbacks, the small victories. That's not natural for most of us.
But wasn't there a risk in that? Couldn't it have made things harder?
Possibly. But he seemed to believe that his struggle had value beyond himself—that by showing people what it actually looked like to face this, he was doing something useful. He wasn't performing courage. He was just documenting what was real.
The statement he left behind—it doesn't sound like someone who was defeated.
No. Even at the end, he was thinking about what came next for other people. He wanted to be remembered as someone who tried, who inspired others to try. That's a particular kind of grace.
Do you think his research will continue?
Almost certainly. The immunotherapy work he pioneered is still being developed. But his real legacy might be something else—showing that a scientist can be fully human about their own vulnerability and still be taken seriously.